Teva and Alvotech have announced receipt of the US FDA approval to Selarsdi injection for use as an interchangeable with ...

Pharma major Dr Reddy’s Laboratories Ltd’s consolidated net profit increased 21% in the fourth quarter ended March 31, 2025 ...

The updated recommendations also provide guidance on antirheumatic drug use through lactation and in male patients trying to ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...

Thank you for joining us today for the Dr. Reddy's earnings conference call covering the quarter and full year ended March 31, 2025. We appreciate your time and participation. Joining us today is the ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

Alvotech and Teva noted that they have three additional biosimilar candidates under review by the US regulator: a proposed biosimilar for Simponi (golimumab) and Simponi Aria (golimumab), AVT05 ...

AVT05 is a biosimilar candidate for Simponi® and Simponi Aria® (golimumab). Golimumab is a monoclonal antibody that inhibits tumor necrosis factor alpha (TNF alpha). Elevated TNF alpha levels ...

In this Healio video, Edward L. Barnes, MD, MPH, associate professor of medicine, co-director of the Multidisciplinary IBD Center and associate fellowship program director at the University of North ...